Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
Status:
Completed
Trial end date:
2019-11-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine if an investigational medication called SelK2
works in preventing a condition called "venous thromboembolism" (VTE) in patients having a
total knee replacement. SelK2 has been designed to attach to a protein found on blood cells
and blood vessels. By attaching to this protein, SelK2 is designed to decrease the
inflammatory process in the blood vessel wall that leads to the formation of blood clots in
the vessel (called thrombosis). By decreasing the inflammatory process, SelK2 may reduce the
risk of VTE following joint replacement surgery. In addition, because SelK2 is not a blood
thinner, it is expected that the risk for bleeding will also be reduced.